DrugBiological
Certolizumab Pegol clinical trials
Also written CDP870 and Certolizumab.
- studies test it
- 98
- open now
- 7
- in phase 3
- 58
- first study started
- 2002
Keep track of what changes. Save the Certolizumab Pegol studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
98 studies that test it; most in 2010 (11)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2003 | 3 |
| 2004 | 3 |
| 2005 | 6 |
| 2006 | 8 |
| 2007 | 7 |
| 2008 | 8 |
| 2009 | 7 |
| 2010 | 11 |
| 2011 | 7 |
| 2012 | 4 |
| 2013 | 4 |
| 2014 | 7 |
| 2015 | 8 |
| 2016 | 1 |
| 2017 | 4 |
| 2020 | 3 |
| 2021 | 2 |
| 2023 | 1 |
| 2025 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 8
- Phase 2
- 14
- Phase 3
- 58
- Phase 4
- 17
- No phase
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 73 · Other 25
UCB Pharma (36) · UCB BIOSCIENCES GmbH (6) · UCB Pharma SA (6) · UCB Biopharma SRL (5) · UCB Biopharma S.P.R.L. (5) · Astellas Pharma Inc (4) · Korea Otsuka Pharmaceutical Co., Ltd. (2) · University of Erlangen-Nürnberg Medical School (2)
Often tested with
Tested in the same studies.
Adalimumab (9) · Methotrexate (7) · Infliximab (7) · Etanercept (6) · Abatacept (6) · Hydroxychloroquine (4) · Sulfasalazine (4) · Leflunomide (4)
Studies
Open first, then newest update. How each study uses Certolizumab Pegol is read from its arms, and is right about nine times in ten.
Testing it · 98
- Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder ArthroplastyRecruitingPhase 2NYU Langone HealthNCT07138898Written as Certolizumab
- Treatment of Rheumatoid Arthritis With DMARDs: Predictors of ResponseRecruitingPhase 3University of NebraskaNCT03414502Written as Certolizumab
- Utilization of a Microdevice for Psoriasis and Atopic DermatitisNot yet recruitingPhase 4University of California, San FranciscoNCT07352566Written as Certolizumab
- IMPACT Study: IMProve Pregnancy in APS With Certolizumab TherapyRecruitingPhase 2David Ware BranchNCT03152058Written as Certolizumab Pegol
- Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained RemissionRecruitingNot applicableMarmara UniversityNCT07491913Written as Certolizumab Pegol
- Certolizumab in Recurrent Implantation Failure (RIF)RecruitingPhase 3Assistance Publique - Hôpitaux de ParisNCT05930613Written as Certolizumab (CIMZIA® ; TNF-α antagonist)
- Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic ArthritisRecruitingPhase 3University of Erlangen-Nürnberg Medical SchoolNCT04610476Written as Certolizumab pegol
- Pediatric Arthritis Study of Certolizumab PegolCompletedPhase 3UCB BIOSCIENCES GmbHNCT01550003Written as Certolizumab Pegol (CZP)
- A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid ArthritisCompletedPhase 3UCB Pharma SANCT01519791Written as Certolizumab Pegol
- A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid ArthritisCompletedPhase 3UCB PharmaNCT01521923Written as Certolizumab Pegol + Methotrexate (MTX)
- A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque PsoriasisCompletedPhase 3UCB Biopharma SRLNCT04123795Written as Certolizumab pegol
- A Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis (AU) Flares in Axial Spondyloarthritis Subjects With a Documented History of AUCompletedPhase 4UCB Biopharma SRLNCT03020992Written as Certolizumab Pegol
- Efficacy Confirmation Study of CDP870 in Early Rheumatoid ArthritisCompletedPhase 3Astellas Pharma IncNCT01451203Written as CZP
- IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIACompletedPhase 4University of Illinois at ChicagoNCT02451748Written as Certolizumab pegol (CDP870, tradename Cimzia)(prefilled syringes at the dose of 200mg)
- A Study to Assess the Pharmacokinetics of Certolizumab Pegol in Adults With Active Rheumatoid ArthritisCompletedPhase 1UCB Biopharma SRLNCT04740814Written as Certolizumab pegol
- A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing SpondylitisCompletedPhase 2UCB Biopharma SRLNCT03215277Written as Certolizumab pegol
- Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung AdenocarcinomasCompletedPhase 1Memorial Sloan Kettering Cancer CenterNCT02120807Written as Certolizumab
- Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of ASCompletedPhase 3UCB BIOSCIENCES GmbHNCT02552212Written as Certolizumab Pegol
- Dose Reduction for Early Rheumatoid Arthritis Patients With Low Disease ActivityStatus unknownPhase 4Karolinska InstitutetNCT02466581Written as Cimzia
- Active Conventional Therapy Compared to Three Different Biologic Treatments in Early Rheumatoid Arthritis With Subsequent Dose ReductionStatus unknownPhase 4Karolinska InstitutetNCT01491815Written as Cimzia
See all 98 studies that test Certolizumab Pegol →
Given in every arm · 4 — Certolizumab Pegol is usual care beside what is tested
- Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With SurgeryRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT04991025Written as Certolizumab
- A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid ArthritisCompletedPhase 2Janssen Research & Development, LLCNCT06028438Written as Certolizumab
- Multiple Dose Study of UCB4940 as add-on to Certolizumab Pegol in Subjects With Rheumatoid ArthritisCompletedPhase 2UCB CelltechNCT02430909Written as Certolizumab Pegol
- Cimzia Versus Cimzia Plus Azathioprine in the Treatment of Active Crohn's DiseaseStatus unknownPhase 3Gastroenterology Research of AmericaNCT01817972Written as Certolizumab pegol
As the comparator · 1 — what is tested is compared with Certolizumab Pegol
Codes
What other systems call Certolizumab Pegol · ClinicalTrials.gg INT006523
- MeSH (NLM) D000068582Certolizumab PegolConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) UMD07X179ECERTOLIZUMAB PEGOLConfirmed FDA, NLM
- RxNorm 709271One source FDA
- NCI Thesaurus C80972Certolizumab PegolOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000068582 | Certolizumab Pegol | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | UMD07X179E | CERTOLIZUMAB PEGOL | Confirmed FDA, NLM |
| RxNorm | 709271 | — | One source FDA |
| NCI Thesaurus | C80972 | Certolizumab Pegol | One source FDA |
Also registered as certolizumab (UNII G6ADW90R16 · RxNorm 709271).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.